Enzyme replacement therapy with Fabryzme results in a rapid and sustained decrease in plasma GL-3 levels and most patients. Periodic testing for GL-3 levels in plasma is recommended as part of the minimal schedule of assessments from the Fabry Registry prior to the start of treatment come every three months for the first 18 months of treatment and then every six months.
Frozen (preferred) - 3 months
Freeze thaw cycles x 6
Clotted or severely hemolyzed plasma samples